RCM
DMIIR

Radcliffe Capital Management’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Radcliffe Capital Management’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.3K Hold
575,000
– – ﹤0.01% 335
2025
Q4 		$74.8K Buy
+575,000
New +$82.1K ﹤0.01% 244

Other funds holding DMIIR

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Radcliffe Capital Management's DMIIR Position: Q1 2026 in Review

Radcliffe Capital Management held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q1 2026 at 575,000 shares worth $40.3K. The position accounts for ﹤0.01% of the portfolio, ranked #335.

Radcliffe Capital Management first reported a position in DMIIR in Q4 2025 and has held it in 2 quarters since. The position peaked at $74.8K in Q4 2025. 57 funds tracked by Wall St. Rank hold DMIIR as of Q1 2026.

  • Radcliffe Capital Management held 575,000 shares of Drugs Made In America Acquisition II Corp Right worth $40.3K as of Q1 2026.
  • Radcliffe Capital Management left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition II Corp Right made up ﹤0.01% of Radcliffe Capital Management's portfolio in Q1 2026, its #335 holding.
  • Radcliffe Capital Management first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 2 quarters since.
  • Radcliffe Capital Management's Drugs Made In America Acquisition II Corp Right position peaked at $74.8K in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.